Table 2.

For each clinical or demographic characteristic, the statistical test results on whether the data instances linking to future asthma-related hospital encounters and those linking to no future asthma-related hospital encounter had the same distribution.

Characteristics		P value for the 2012-2016 data	P value for the 2017 data
Age (years)		<.001 a,b	<.001 a
Gender		<.001 c	.01 c
Race		<.001 c	<.001 c
Ethnicity		<.001 c	<.001 c
Insurance category		<.001 c	<.001 c
Number of years since the first asthma-coded encounter in the data set		.78a	.006 a
Asthma medication fill
	Inhaled corticosteroid	<.001 c	<.001 c
	Inhaled corticosteroid and long-acting beta-2 agonist combination	<.001 c	<.001 c
	Leukotriene modifier	<.001 c	<.001 c
	Long-acting beta-2 agonist	<.001 c	<.001 c
	Mast cell stabilizer	>.99c	>.99c
	Short-acting, inhaled beta-2 agonist	<.001 c	<.001 c
	Systemic corticosteroid	<.001 c	<.001 c
Comorbidity
	Allergic rhinitis	<.001 c	<.001 c
	Anxiety or depression	<.001 c	<.001 c
	Bronchopulmonary dysplasia	<.001 c	>.99c
	Chronic obstructive pulmonary disease	<.001 c	<.001 c
	Cystic fibrosis	>.99c	.52c
	Eczema	<.001 c	<.001 c
	Gastroesophageal reflux	<.001 c	<.001 c
	Obesity	<.001 c	<.001 c
	Premature birth	<.001 c	<.001 c
	Sinusitis	.33c	.06c
	Sleep apnea	.003 c	<.001 c
Smoking status		<.001 c	<.001 c

^aP values obtained by performing the Cochran-Armitage trend test [39].

^bP values <.05 marked in italics.

^cP values obtained by performing the chi-square two-sample test.